Picture of Hanmi Pharm logo

128940 — Hanmi Pharm News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Sanofi sees strong profit growth from 2018, to cut costs

PARIS, Nov 6 (Reuters) - Sanofi  SASY.PA  said investment in 
products to compensate for declining diabetes sales will prevent 
significant profit growth in the next two years, adding that 
earnings would outpace sales from 2018. 
    The French drugmaker said on Friday that it would slash 
costs by 1.5 billion euros ($1.63 billion) by 2018 as it aims to 
remain a diversified healthcare company while many competitors 
have chosen to specialise in recent years. 
    Sanofi said it expected six product launches to generate 
sales of 12 billion to 14 billion euros over the next five years 
in the hope of compensating for its struggling diabetes 
business, its main division and profit centre. 
    "As a result of investments in launches, headwinds in 
diabetes and the phasing of cost savings, Sanofi does not expect 
to show any meaningful bottom-line growth over 2016-2017," the 
company said in a statement. 
    "Beginning in 2018, however, Sanofi expects to grow business 
earnings per share faster than sales, reflecting its improved 
sales mix and the full capture of cost efficiencies." 
    In a separate announcement, Sanofi said it had entered in a 
licence agreement in diabetes with U.S. Lexicon Pharmaceuticals 
 LXRX.O , following a deal with Korea's Hanmi Pharmaceutical 
 128940.KS  on Thursday.  ID:nFWN13009A   ID:nL8N1303GH  
 ($1 = 0.9192 euros) 
 
 (Reporting by Matthias Blamont; Editing by James Regan) 
 ((matthias.blamont@thomsonreuters.com ; +33 1 4949 5054; 
Reuters Messaging: matthias.blamont.reuters.com@reuters.net)) 
 
Keywords: SANOFI STRATEGY/

Recent news on Hanmi Pharm

See all news